Results of the TUXEDO Trial Reported at TCT 2015 and Published in the New England Journal of Medicine

SAN FRANCISCO – October 14, 2015 – Results of the TUXEDO trial, designed to compare two types of stents in diabetic patients, found that paclitaxel-eluting stents failed to meet non-inferiority criterion when compared to everolimus-eluting stents for the primary endpoint of target-vessel failure at one year.

Findings from the trial were reported today at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. The study was also published in the New England Journal of Medicine.

The optimal drug-eluting stent for coronary artery disease in a diabetic population has often been debated, with contradictory results from past studies comparing paclitaxel-eluting stents versus stents eluting rapamycin analogues (sirolimus, zotarolimus or everolimus). In the absence of an adequately powered study to assess clinical outcomes, a definitive conclusion has not yet been found.

In this investigator-initiated study, 1,830 patients with diabetes mellitus and coronary artery disease undergoing percutaneous intervention at 46 centers in India were randomly assigned to receive either a paclitaxel-eluting stent or everolimus-eluting stent in a non-inferiority trial. The primary endpoint was target-vessel failure defined as a composite of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization at one-year follow-up.

In this trial, paclitaxel-eluting stents did not meet the non-inferiority criterion for target-vessel failure when compared to everolimus-eluting stents at one year (5.6% vs. 2.9%; relative risk=1.89; 95% CI=1.20 to 2.99; risk difference=2.7%; 95% CI=0.78% to 4.48%; Pnoninferiority=0.38). Notably, there was a significantly higher one-year rate of target-vessel failure (P=0.005), myocardial infarction (3.2% vs. 1.2%, P=0.004), stent thrombosis (2.1% vs. 0.4%, P=0.002), target-vessel revascularization (3.4% vs. 1.2%; P=0.002) and target-lesion revascularization (3.4% vs. 1.2%; P=0.002) in the paclitaxel-eluting stent group compared with the everolimus-eluting stent group.

“In patients with diabetes and coronary artery disease, paclitaxel-eluting stents were inferior to everolimus-eluting stents for the primary outcome of target-vessel failure and resulted in higher rates of target-vessel failure, myocardial infarction, stent thrombosis, and target-vessel revascularization at one year. Everolimus-eluting stents were superior to paclitaxel-eluting stents for several end points including target-vessel failure, myocardial infarction, and stent thrombosis,” said lead investigator Upendra Kaul, MD. Dr. Kaul is Executive Director and Dean, Cardiology at the Fortis Escorts Heart Institute and Fortis Vasant Kunj in New Delhi, India.

“The TUXEDO trial supports the efficacy and safety of limus-eluting stents over paclitaxel-eluting stents in diabetics. The study also questions the ability to translate the findings of previous trials comparing PCI using first-generation stents to coronary bypass surgery in diabetics, as opposed to the current practice of using second-generation drug-eluting stents,” Dr. Kaul said.

The TUXEDO trial was an investigator initiated study sponsored by Boston Scientific Corporation and a commitment to ensure consistent availability of the Xience Prime stent for the trial was provided by Abbott Vascular. Dr. Kaul reported research grant and lecture fees from Boston Scientific and lecture fees from Abbott Vascular.

Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Senior Manager, External Relations
Tel: 646-434-4608